Content Summary : Biomarkers for Lung Cancer Dr. Semmes and Cazares have discovered protein biomarkers by mass spectroscopy (MS) methods for use in the diagnosis of lung cancer. The invention provides for methods using one or more biomarkers, including but not limited to MS methods and immunoassays, to aid in the diagnosis of lung cancer. Lung Cancer Diagnostics Lung cancer is the most common cancer in the world. However, by the time most patients seek medical attention for the symptoms of lung cancer, the disease is untreatable. One current limitation in diagnosis is that lung cancer is typically detected through chest x-ray and sputum cytology. As a result, a considerable amount of research has been directed toward early detection of tumor markers before the cancer becomes clinically observable and unresponsive to treatment. Many different research groups have brought forward potential lung cancer biomarkers; however, none have proven to be useful in a clinical setting for the early diagnosis of lung cancer. The ability to make a diagnosis early would be of high value to the patient since it would allow for early therapeutic intervention. Currently, an accurate diagnosis is usually only made when the disease has further progressed and is less responsive or unresponsive to therapeutic intervention.